130
Views
8
CrossRef citations to date
0
Altmetric
Theme: Schizophrenia - Key Paper Evaluation

Prenatal immune activation and subsequent peripubertal stress as a new model of schizophrenia

, &
Pages 747-750 | Published online: 09 Jan 2014

References

  • Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 167(3), 261–280 (2010).
  • Meyer U, Feldon J, Yee BK. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr. Bull. 35(5), 959–972 (2009).
  • Eyles D, Feldon J, Meyer U. Schizophrenia: do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed developmental rodent models. Transl. Psychiatry 2, e81 (2012).
  • Kneeland RE, Fatemi SH. Viral infection, inflammation and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 42, 35–48 (2013).
  • Brown AS. The environment and susceptibility to schizophrenia. Prog. Neurobiol. 93(1), 23–58 (2011).
  • Bayer TA, Falkai P, Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the ‘two hit hypothesis’. J. Psychiatr. Res. 33(6), 543–548 (1999).
  • Yee N, Ribic A, de Roo CC, Fuchs E. Differential effects of maternal immune activation and juvenile stress on anxiety-like behaviour and physiology in adult rats: no evidence for the ‘double-hit hypothesis’. Behav. Brain Res. 224(1), 180–188 (2011).
  • Giovanoli S, Engler H, Engler A et al. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science 339(6123), 1095–1099 (2013).
  • Pacheco-López G, Giovanoli S, Langhans W, Meyer U. Priming of metabolic dysfunctions by prenatal immune activation in mice: relevance to schizophrenia. Schizophr. Bull. 39(2), 319–329 (2013).
  • Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol. Psychiatry 59(6), 546–554 (2006).
  • Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70(7), 663–671 (2011).
  • van Berckel BN, Bossong MG, Boellaard R et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry 64(9), 820–822 (2008).
  • Hashimoto K. Microglial activation in schizophrenia and minocycline treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(7), 1758–1759; author reply 1760 (2008).
  • Hsiao EY, Patterson PH. Activation of the maternal immune system induces endocrine changes in the placenta via IL-6. Brain Behav. Immun. 25(4), 604–615 (2011).
  • Forrest CM, Khalil OS, Pisar M, Smith RA, Darlington LG, Stone TW. Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly (I:C) changes synaptic proteins, N-methyl-d-aspartate receptors and neurogenesis markers in offspring. Mol. Brain 9(5), 22 (2012).
  • Holloway T, Moreno JL, Umali A et al. Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: role of maternal immune system. J. Neurosci. 33(3), 1088–1098 (2013).
  • Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. doi:10.1007/s00406-013-0399-y (2013) (Epub ahead of print).
  • Abazyan B, Nomura J, Kannan G et al. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol. Psychiatry 68(12), 1172–1181 (2010).
  • Niwa M, Jaaro-Peled H, Tankou S et al. Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids. Science 339(6117), 335–339 (2013).
  • Suo L, Zhao L, Si J et al. Predictable chronic mild stress in adolescence increases resilience in adulthood. Neuropsychopharmacology 38(8), 1387–1400 (2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.